...
- Group 1 is a control group of 20 subjects, 10 male and 10 female, which are to be dosed with vehicle once per day for 14 days, given a 7-day rest period, dosed again with vehicle once per day for 14 days, given a second 7-day rest period, and dosed with vehicle once per day for the final 14 days.
- Group 2 is a group of 20 subjects, 10 male and 10 female, which are to be dosed at 50 mg/kg of product once per day for 14 days, given a 7-day rest period, dosed at 800 mg/kg once per day for 14 days, given a second 7-day rest period, and dosed at 400 mg/kg of product once per day for the final 14 days.
- Group 3 is a group of 20 subjects, 10 male and 10 female, which are to be dosed at 400 mg/kg of product once per day for 14 days, given a 7-day rest period, dosed at 50 mg/kg of product once per day for 14 days, given a second 7-day rest period, and dosed at 800 mg/kg of product once per day for the final 14 days.
- Group 4 is a group of 20 subjects, 10 male and 10 female, which are to be dosed at 800 mg/kg of product once per day for 14 days, given a 7-day rest period, dosed at 400 mg/kg of product once per day for 14 days, given a second 7-day rest period, and dosed at 50 mg/kg of product once per day for the final 14 days.
...
This example shows the start and end rules and durations for the different treatment product exposure elements, indicating whether they follow a treatment product exposure or nontreatment nonexposure element.
| Dataset wrap |
|---|
|
| Jira |
|---|
| showSummary | false |
|---|
| server | Issue Tracker (JIRA) |
|---|
| serverId | 85506ce4-3cb3-3d91-85ee-f633aaaf4a45 |
|---|
| key | TOBA-216 |
|---|
|
| Dataset2 |
|---|
| Row | STUDYID | DOMAIN | ETCD | ELEMENT | TESTRL | TEENRL | TEDUR |
|---|
| 1 | TDM5 | TE | SCRN | Screen | Start of PretreatmentPreexposure | 10 days after start of Element | P10D | | 2 | TDM5 | TE | CONTROL | Vehicle Control | First dosing with vehicle control following a nontreatment nonexposure Element | 14 days after start of Element | P14D | | 3 | TDM5 | TE | REST | Rest for 7 days | 1 day after last dose in a treatment product exposure Element | 7 days after start of Element | P7D | | 4 | TDM5 | TE | 50A | 50 mg/kg Drug A, once daily | First dosing with 50 mg/kg Drug a following a nontreatment nonexposure Element | 14 days after start of Element | P14D | | 5 | TDM5 | TE | 400A | 400 mg/kg Drug A, once daily | First dosing with 400 mg/kg Drug a following a nontreatment nonexposure Element | 14 days after start of Element | P14D | | 6 | TDM5 | TE | 800A | 800 mg/kg Drug A, once daily | First dosing with 800 mg/kg Drug a following a nontreatment nonexposure Element | 14 days after start of Element | P14D | |
|
...
| Dataset wrap |
|---|
|
| Dataset2 |
|---|
| Row | STUDYID | DOMAIN | ARMCD | ARM | TAETORD | ETCD | ELEMENT | TABRANCH | EPOCH |
|---|
| 1 | TDM5 | TA | 1 | Control | 1 | SCRN | Screen | Randomized to Group 1 | PRE-TREATMENTEXPOSURE | | 2 | TDM5 | TA | 1 | Control | 2 | CONTROL | Vehicle Control |
| TREATMENTEXPOSURE | | 3 | TDM5 | TA | 1 | Control | 3 | REST | Rest for 7 days |
| WASHOUT | | 4 | TDM5 | TA | 1 | Control | 4 | CONTROL | Vehicle Control |
| TREATMENTEXPOSURE | | 5 | TDM5 | TA | 1 | Control | 5 | REST | Rest for 7 days |
| WASHOUT | | 6 | TDM5 | TA | 1 | Control | 6 | CONTROL | Vehicle Control |
| TREATMENTEXPOSURE | | 7 | TDM5 | TA | 2 | 50-800-400 | 1 | SCRN | Screen | Randomized to Group 2 | PRE-TREATMENTEXPOSURE | | 8 | TDM5 | TA | 2 | 50-800-400 | 2 | 50A | 50 mg/kg Drug A |
| TREATMENTEXPOSURE | | 9 | TDM5 | TA | 2 | 50-800-400 | 3 | REST | Rest for 7 days |
| WASHOUT | | 10 | TDM5 | TA | 2 | 50-800-400 | 4 | 800A | 800 mg/kg Drug A |
| TREATMENTEXPOSURE | | 11 | TDM5 | TA | 2 | 50-800-400 | 5 | REST | Rest for 7 days |
| WASHOUT | | 12 | TDM5 | TA | 2 | 50-800-400 | 6 | 400A | 400 mg/kg Drug A |
| TREATMENTEXPOSURE | | 13 | TDM5 | TA | 3 | 400-50-800 | 1 | SCRN | Screen | Randomized to Group 3 | PRE-TREATMENTEXPOSURE | | 14 | TDM5 | TA | 3 | 400-50-800 | 2 | 400A | 400 mg/kg Drug A |
| TREATMENTEXPOSURE | | 15 | TDM5 | TA | 3 | 400-50-800 | 3 | REST | Rest for 7 days |
| WASHOUT | | 16 | TDM5 | TA | 3 | 400-50-800 | 4 | 50A | 50 mg/kg Drug A |
| TREATMENTEXPOSURE | | 17 | TDM5 | TA | 3 | 400-50-800 | 5 | REST | Rest for 7 days |
| WASHOUT | | 18 | TDM5 | TA | 3 | 400-50-800 | 6 | 800A | 800 mg/kg Drug A |
| TREATMENTEXPOSURE | | 19 | TDM5 | TA | 4 | 800-400-50 | 1 | SCRN | Screen | Randomized to Group 4 | PRE-TREATMENTEXPOSURE | | 20 | TDM5 | TA | 4 | 800-400-50 | 2 | 800A | 800 mg/kg Drug A |
| TREATMENTEXPOSURE | | 21 | TDM5 | TA | 4 | 800-400-50 | 3 | REST | Rest for 7 days |
| WASHOUT | | 22 | TDM5 | TA | 4 | 800-400-50 | 4 | 400A | 400 mg/kg Drug A |
| TREATMENTEXPOSURE | | 23 | TDM5 | TA | 4 | 800-400-50 | 5 | REST | Rest for 7 days |
| WASHOUT | | 24 | TDM5 | TA | 4 | 800-400-50 | 6 | 50A | 50 mg/kg Drug A |
| TREATMENTEXPOSURE |
|
|
Trial Sets
In this example, there are 4 trial sets. The experimental factors considered are type of treatment exposure (vehicle control or compoundintervention article) and sequencing of treatment exposure levels. The applicant is providing the arm code, applicant-defined group code, group label, control type, dose level and units, and planned number of subjects (total) only.
| Dataset wrap |
|---|
|
| Dataset2 |
|---|
| Row | STUDYID | DOMAIN | SETCD | SET | TXSEQ | TXPARMCD | TXPARM | TXVAL |
|---|
| 1 | TDM5 | TX | 1 | Group 1, (Vehicle Control Name) once daily for each of 3 dosing periods of 14 days each with 7-day rests between | 1 | ARMCD | Arm Code | 1 | | 2 | TDM5 | TX | 1 | Group 1, (Vehicle Control Name) once daily for each of 3 dosing periods of 14 days each with 7-day rests between | 2 | SPGRPCD | Applicant-Defined Group Code | 1 | | 3 | TDM5 | TX | 1 | Group 1, (Vehicle Control Name) once daily for each of 3 dosing periods of 14 days each with 7-day rests between | 3 | GRPLBL | Group Label | Group 1, Control | | 4 | TDM5 | TX | 1 | Group 1, (Vehicle Control Name) once daily for each of 3 dosing periods of 14 days each with 7-day rests between | 4 | TCNTRL | Control Type | VEHICLE CONTROL | | 5 | TDM5 | TX | 1 | Group 1, (Vehicle Control Name) once daily for each of 3 dosing periods of 14 days each with 7-day rests between | 5 | TRTDOSDOS | Dose Level | 0 | | 6 | TDM5 | TX | 1 | Group 1, (Vehicle Control Name) once daily for each of 3 dosing periods of 14 days each with 7-day rests between | 6 | TRTDOSUITVDOSU | Dose Units | mg/kg/day | | 7 | TDM5 | TX | 1 | Group 1, (Vehicle Control Name) once daily for each of 3 dosing periods of 14 days each with 7-day rests between | 7 | SPLANSUB | Planned Number of Subjects | 20 | | 8 | TDM5 | TX | 2 | Group 2, (Compound Intervention Name) once daily dosing in sequence: 50-800-400 mg/kg (14 days each) with 7-day rests between | 8 | ARMCD | Arm Code | 2 | | 9 | TDM5 | TX | 2 | Group 2, (Compound Intervention Name) once daily dosing in sequence: 50-800-400 mg/kg (14 days each) with 7-day rests between | 9 | SPGRPCD | Applicant-Defined Group Code | 2 | | 10 | TDM5 | TX | 2 | Group 2, (Compound Intervention Name) once daily dosing in sequence: 50-800-400 mg/kg (14 days each) with 7-day rests between | 10 | GRPLBL | Group Label | Group 2, 50-800-400 mg/kg/day | | 11 | TDM5 | TX | 2 | Group 2, (Compound Intervention Name) once daily dosing in sequence: 50-800-400 mg/kg (14 days each) with 7-day rests between | 11 | TRTDOSITVDOS | Dose Level | SEE PROTOCOL | | 12 | TDM5 | TX | 2 | Group 2, (Compound Intervention Name) once daily dosing in sequence: 50-800-400 mg/kg (14 days each) with 7-day rests between | 12 | TRTDOSUITVDOSU | Dose Units | SEE PROTOCOL | | 13 | TDM5 | TX | 2 | Group 2, (Compound Intervention Name) once daily dosing in sequence: 50-800-400 mg/kg (14 days each) with 7-day rests between | 13 | SPLANSUB | Planned Number of Subjects | 20 | | 14 | TDM5 | TX | 3 | Group 3, (Compound Intervention Name) once daily dosing in sequence: 400-50-800 mg/kg (14 days each) with 7-day rests between | 14 | ARMCD | Arm Code | 3 | | 15 | TDM5 | TX | 3 | Group 3, (Compound Intervention Name) once daily dosing in sequence: 400-50-800 mg/kg (14 days each) with 7-day rests between | 15 | SPGRPCD | Applicant-Defined Group Code | 3 | | 16 | TDM5 | TX | 3 | Group 3, (Compound Intervention Name) once daily dosing in sequence: 400-50-800 mg/kg (14 days each) with 7-day rests between | 16 | GRPLBL | Group Label | Group 3, 400-50-800 mg/kg/day | | 17 | TDM5 | TX | 3 | Group 3, (Compound Intervention Name) once daily dosing in sequence: 400-50-800 mg/kg (14 days each) with 7-day rests between | 17 | TRTDOSITVDOS | Dose Level | SEE PROTOCOL | | 18 | TDM5 | TX | 3 | Group 3, (Compound Intervention Name) once daily dosing in sequence: 400-50-800 mg/kg (14 days each) with 7-day rests between | 18 | TRTDOSUITVDOSU | Dose Units | SEE PROTOCOL | | 19 | TDM5 | TX | 3 | Group 3, (Compound Intervention Name) once daily dosing in sequence: 400-50-800 mg/kg (14 days each) with 7-day rests between | 19 | SPLANSUB | Planned Number of Subjects | 20 | | 20 | TDM5 | TX | 4 | Group 4, (Compound Intervention Name) once daily dosing in sequence: 800-400-50 mg/kg (14 days each) with 7-day rests between | 20 | ARMCD | Arm Code | 4 | | 21 | TDM5 | TX | 4 | Group 4, (Compound Intervention Name) once daily dosing in sequence: 800-400-50 mg/kg (14 days each) with 7-day rests between | 21 | SPGRPCD | Applicant-Defined Group Code | 4 | | 22 | TDM5 | TX | 4 | Group 4, (Compound Intervention Name) once daily dosing in sequence: 800-400-50 mg/kg (14 days each) with 7-day rests between | 22 | GRPLBL | Group Label | Group 4, 800-400-50 mg/kg/day | | 23 | TDM5 | TX | 4 | Group 4, (Compound Intervention Name) once daily dosing in sequence: 800-400-50 mg/kg (14 days each) with 7-day rests between | 23 | TRTDOSITVDOS | Dose Level | SEE PROTOCOL | | 24 | TDM5 | TX | 4 | Group 4, (Compound Intervention Name) once daily dosing in sequence: 800-400-50 mg/kg (14 days each) with 7-day rests between | 24 | TRTDOSUITVDOSU | Dose Units | SEE PROTOCOL | | 25 | TDM5 | TX | 4 | Group 4, (Compound Intervention Name) once daily dosing in sequence: 800-400-50 mg/kg (14 days each) with 7-day rests between | 25 | SPLANSUB | Planned Number of Subjects | 20 |
|
|